Listado de Ponencias del XVI Symposium GETNE 2020
MESA1
Translationonal research in endocrine malignancies: from the bench to the bed
Moderators:
Dr. Oriol Casanovas. Servicio de Biomedicina. ICO- L’Hospitalet, Barcelona
Dr. Justo Castaño. Instituto Maimónides de Investigación Biomédica. Hospital Universitario Reina Sofía de Córdoba
Epigenome in PanNETs
Dr. Ilaria Marinoni. Experimental Pathology. University of Bern, Switzerland
Inflammation as a key hallmark in neuroendocrine tumors
Prof. Giovanni Vitale. University of Milan, Istituto Auxologico Italiano, Milan, Italy
Role of hypoxia in endocrine malignancies
Dr. Rodrigo Toledo. Grupo de tumores gastrointestinales y endocrinos. Vall d´Hebron Institute of Oncology (VHIO), Barcelona
MESA2
Clinical challenges in endocrine malignancies
Moderators:
Dr. Maribel del Olmo. Servicio de Endocrinología. Hospital Universitari i Politècnic La Fe, Valencia
Dr. Elena Martín. Servicio de Cirugía General. Hospital Universitario de La Princesa, Madrid
Surgical management of primary tumors in stage IV gastroenteropancreatic and thoracic neuroendocrine neoplams
Dr. Elena Martín. Servicio de Cirugía General. Hospital Universitario de La Princesa, Madrid
Different scenarios for hormone-release control before invasive procedures in endocrine malignancies
Dr. Wouter de Herder. Department of Endocrinology. Erasmus MC. Rotherdam. The Netherlands
Optimization of molecular imaging in neuroendocrine tumors
Dr. Marc Simó. Servicio de Medicina Nuclear. Hospital Universitari Vall d´Hebron, Barcelona
Locoregional therapy for liver metastases in neuroendocrine tumors in 2020: new techniques may open new indications?
Dr. Joan Novo. Servicio de Radiología Intervencionista. Hospital Universitario La Paz, Madrid
MESA3
What’s new in 2020 on systemic therapies for advanced endocrine tumors?
Moderators:
Dr. Ana Custodio. Servicio de Oncología Médica. Hospital Universitario La Paz, Madrid
Dr. Enrique Grande. Servicio de Oncología Médica. Centro Oncológico M.D. Anderson, Madrid
Gastroenteropancreatic & thoracic neuroendocrine tumors
Dr. Rocío García Carbonero. Servicio de Oncología Médica. Hospital Universitario 12 de Octubre, Madrid
Malignant pheochromocytoma and paraganglioma
Dr. Eric Baudin. Endocrine tumors committee Institut Gustave Roussy, Villejuif, France
Tumor agnostics in endocrine malignancies
Dr. Vivek Subbiah. Department of Investigational Cancer. Therapeutics, Division of Cancer Medicine. MD Anderson Cancer Center, Houston, USA
MESA4
Practical approaches to treat complex tumors
Moderators:
Dr. Paula Jiménez Fonseca. Servicio de Oncología Médica. Hospital Universitario Central de Asturias, Oviedo
Dr. Mónica Marazuela. Servicio de Endocrinología. Hospital Universitario de La Princesa, Madrid
Anaplastic thyroid cancer
Dr. María Cabanillas. Department of Endocrine Neoplasia and Hormonal Disorders. The University of Texas. MD Anderson Cancer Center, Houston, Texas
Adrenocortical carcinoma
Dr. Alfredo Berruti. Department of Medicine and Surgery. Università degli Studi di Brescia, Italy
Merkel Cell carcinoma
Dr. Lars Bastholt. Department of Oncology. Odense University Hospital, Denmark
Virtual delivery of GETNE 2020 research grant
Dr. Jorge Barriuso. Faculty of Biology, Medicine and Health. University of Manchester, Manchester, United Kingdom
Reporting of results of 2015 research grant
Dr. Nuria Valdés. Servicio de Endocrinología y Nutrición. Hospital Universitario de Cabueñes, Gijón
MESA5
Treating endocrine malignancies beyond guidelines
Moderators:
Dr. Javier Aller. Servicio de Endocrinología. Hospital Universitario Puerta de Hierro, Majadahonda, Madrid
Dr. Mercedes Mitjavila. Servicio de Medicina Nuclear. Hospital Universitario Puerta de Hierro, Majadahonda, Madrid
Clinical evidence of peptide receptor radionucleotide therapy beyond NETTER-1
Dr. Virginia Pubul. Servicio de Medicina Nueclear. Complejo Hospitalario Universitario, Santiago de Compostela
Refractory thyroid cancer (differentiated and medullary): how can we manage patients atier progression to approved multikinase inhibitors?
Dr. Marcia Brose. Department of Otorhinolaryngology: Head and Neck Surgery, and Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA. USA
Predicting treatment algorithms for neuroendocrine tumors within the next five years: can we expect higher levels of evidence for sequential therapies?
Dr. Marianne Pavel. Chair of Endocrinology. Friedrich Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
MESA6
How can we guarantee the future of endocrine tumor research?
Moderators:
Mrs. Mar Ayllón. PHEiPAS España Chairperson, Castellón
Dr. Jaume Capdevila. Servicio de Oncología Médica. Hospital Universitari Vall d’Hebron, Barcelona
Mrs. Blanca Guarás. NET-ESPAÑA Chairperson, Madrid
Mrs. Aranzazu Sáez. AECAT España Chairperson, Madrid
From the point of view of GETNE
Dr. Jorge Barriuso. Faculty of Biology, Medicine and Health. University of Manchester, Manchester, United Kingdom
From the point of view of patient
Esteve Cusidó. Patient of neuroendocrine tumor. NET – ESPAÑA
From the point of view of coordination in clinical trials
Dr. Lorena Trejo. Servicio de Oncología Médica. Vall d´Hebron Institute of Oncology (VHIO), Barcelona
From the point of view of the new generations: GETNE Academy
Dr. Jorge Hernando. Servicio de Oncología Médica. Vall d ́Hebron Institute of Oncology (VHIO), Barcelona